Advertisement

Internal and Emergency Medicine

, Volume 12, Issue 6, pp 733–735 | Cite as

Analysis of E-cigarette use in the 2014 Eurobarometer survey: calling out deficiencies in epidemiology methods

  • Riccardo Polosa
  • Pasquale CaponnettoEmail author
  • Ray Niaura
  • David Abrams
Open Access
IM - COMMENTARY

Keywords

Electronic cigarette Smoking Epidemiology 

Smoking is a difficult addiction to break with many smokers persisting in tobacco use for numerous years, and typically cycling through multiple periods of remission and relapse [1]. Yet, while smoking cessation may be the most desirable final outcome, substitution of conventional cigarettes by alternative non-combusted forms of nicotine delivery, such as electronic cigarettes (ECs), is now a realistic compromise that is likely to eliminate or substantially reduce exposure to tobacco smoke toxicants [2].

ECs were first marketed 10 years ago, and are now widely used as long-term substitutes for tobacco cigarettes primarily because they share sufficient similarities with bio-behavioural and sensorial aspects of smoking [3]. Designed to enable inhalation of flavoured liquids, in which pharmaceutical grade nicotine may (or may not) be added, these battery-operated vaporizers do not contain tobacco. Nonetheless, ECs are now legally considered to be tobacco products in the European Union and in the United States.

The scientific evidence indicates that ECs are much less harmful than conventional cigarettes [4, 5]. Despite their reduced risk profile, questions remain as to whether ECs are effective aids for smoking cessation, promote uptake by nontobacco users, sustain nicotine dependency via dual use, slow intentions to quit in dual users, or encourage relapse to cigarette use among former smokers [6].

Unfortunately, existing observational and epidemiological studies are largely uninformative due to severe methodological limitations. Much of the early population-level studies on adult EC use have relied on crude measures of use: (such as “once or more in the past 30 days”, or “ever use”) which do not capture frequency, intensity, or reasons for use [7, 8, 9]; such defective definitions of current EC use will include many infrequent users (mostly experimenters unlikely to use ECs regularly), thus abnormally inflating these statistics and providing misleading conclusions about the individual as well as public health impact of ECs. Notably, experimentation with ECs is now associated with an accelerated rate of decline in smoking among youths [10, 11, 12].

More realistic insights of greater public health relevance can be drawn by studies that assess, with greater precision, why, how and what smokers are using as tobacco substitutes. For example, frequency of use (daily vs non-daily) and type of EC device (advanced open tank systems vs basic cigalikes) are associated with cigarette abstinence—daily users of more efficient EC kits are most successful [13, 14]. Specifying the reason for using ECs (to quit smoking vs out of curiosity), as well as the presence of nicotine (vs its absence), are also important determinants of success [15, 16].

Some of these critical measurement issues have been addressed in a recent cross-sectional study of a representative sample of 27,801 respondents from 28 EU member states [17]. In particular, the study herein examines current daily EC use, including current daily nicotine use.

There are several important findings. Among never smokers, only minimal current daily (0.08%) and current daily nicotine-containing EC use (0.04%) is observed. By comparison, daily vaping is reported by 2.31% of current smokers and 2.18% of former smokers, the vast majority of whom reported vaping nicotine. As one would expect, daily EC use is highly prevalent among current and former smokers, but rare in never smokers. Compared to never smokers, current and former smokers are at least 50 times more likely to report daily EC use, which would suggest that vapor products are extremely unlikely to create daily nicotine dependence (just 4 in 10,000 never smokers). Thus, it does not appear that the threat of ECs attracting a new generation of nicotine addicts has materialized.

Considering that ECs are much less harmful alternatives to tobacco cigarettes, and that smoking prevalence in the 2014 Eurobarometer survey is still high at 26.4%, regular EC use of about 2% for the overall sample is disappointingly low, and it is unlikely to have the significant public health impact it could have if a harm reduction strategy was adopted by the public health community. Several factors might have contributed to such low uptake. For example, irresponsible science, careless publishing, and credulous journalism have increasingly fuelled alarmist and deeply misleading stories about potential harm of these products. These stories are now spreading fear and confusion, and have actually resulted in public perceptions shifting in the wrong direction so that ECs are now misperceived as equal to or more harmful than cigarettes, possibly resulting in some users going back to cigarettes, or not being open to even trying them. Moreover, the distortion of the scientific evidence of harms has also been misused and exaggerated thus undermining switching and slowing of speeding up the end game of eliminating smoked tobacco rather than eliminating any and all nicotine product use for adults. Promoting further access to ECs and making these products widely available may offer an opportunity to reduce or prevent some of the otherwise inevitable burden of premature death and disability caused by tobacco smoking [18].

Interactions between changes in smoking behaviour and daily EC use were also investigated. Although the cross-sectional design of the 2014 Eurobarometer survey cannot establish cause and effect, another important finding is that nearly half of all daily EC users have quit smoking completely (by vaping). Clearly, improved characterization of frequency of use as well as nicotine provision appears to play a major role when evaluating smoking cessation. A possible explanation is that regular daily EC use might have assisted many EC users to build up the necessary confidence to do something good for their health, and to stay quit or reduce cigarette consumption. The same logic may also explain the low level of relapse observed in the sample.

EC use is a complex and dynamically evolving behaviour. Its definition and detailed characterization of concurrent EC and cigarette use requires thoughtful and careful assessment. Therefore, to advance knowledge of the impact of EC use on smoking status, it will be necessary to conduct prospective studies considering relevant descriptors of vaping behaviour such as frequency of use (e.g. focusing on daily users, and not just to those who are experimenting), reasons for using ECs (e.g. to quit smoking vs out of curiosity), and product design (e.g. closed vs open systems; nicotine containing vs non-nicotine containing products; etc.). Reasons for vaping, the type of device and e-liquid, frequency of use, and the accompanying sensory and craving-control experiences will have some impact on smoking behaviors (cutting down, quitting). Only carefully conducted longitudinal studies will be able to indicate which combinations of device and human use factors are likely to lead to sustained, beneficial outcomes.

In any case the study by Farsalinos and colleagues [17] is important because by addressing some of the common methodological mistakes present in the vast majority of existing observational and epidemiological studies, it provides a more realistic estimate of current regular EC use, and of its impact on smoking habits. Despite some mixed and negative results from many early epidemiological studies with serious methodological limitations, a common theme that seems to be emerging is that if a smoker persists in seeking out and finding an EC that is satisfying to him/her (including flavors) and persists in regular use, he/she is more likely to switch or quit. By exploring diversities and similarities among different product designs, smokers are now beginning to learn that adoption rates (and consequently the extent of reduction in tobacco consumption), are intimately associated with their efficiency as smoking “sensation” products, with smoking cessation becoming a “collateral benefit” for many smokers switching to regular daily EC use [19, 20, 21].

Notes

Acknowledgements

Authors wish to thank Cuts Ice e-Liquid Laboratories for supporting the publication and open access costs.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any study with human and animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    Caponnetto P, Keller E, Bruno CM, Polosa R (2013) Handling relapse in smoking cessation: strategies and recommendations. Intern Emerg Med 8:7–12CrossRefPubMedGoogle Scholar
  2. 2.
    Polosa R, Rodu B, Caponnetto P, Maglia M, Raciti C (2013) A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J 10:19CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Caponnetto P, Russo C, Bruno CM, Alamo A, Amaradio MD, Polosa R (2013) Electronic cigarette: a possible substitute for cigarettedependence. Monaldi Arch Chest Dis 79:12–19PubMedGoogle Scholar
  4. 4.
    Farsalinos KE, Polosa R (2014) Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. TherAdv Drug Saf 5:67–86CrossRefGoogle Scholar
  5. 5.
    Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerstrom K, Letlape K, Polosa R, Ramsey J, Sweanor D (2016) E-cigarettes are less harmful than smoking. Lancet 387(10024):1160–1162CrossRefPubMedGoogle Scholar
  6. 6.
    Glasser AM, Collins L, Pearson JL, Abudayyeh H, Niaura RS, Abrams DB, Villanti AC (2017) Overview of electronic nicotine delivery systems: a systematic review. Am J Prev Med 52(2):e33–e66CrossRefPubMedGoogle Scholar
  7. 7.
    Giovenco DP, Lewis MJ, Delnevo CD (2014) Factors associated with e-cigarette use: a National Population Survey of Current and Former Smokers. Am J Prev Med 47(4):476–480CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pearson JL, Stanton CA, Cha S, Niaura RS, Luta G, Graham AL (2015) E-cigarettes and smoking cessation: insights and cautions from a secondary analysis of data from a study of online treatment-seeking smokers. Nicotine Tob Res 17(10):1219–1227CrossRefPubMedGoogle Scholar
  9. 9.
    Amato MS, Boyle RG, Levy D (2016) How to define e-cigarette prevalence? Finding clues in the use frequency distribution. Tob Control. 25(e1):e24–e29CrossRefPubMedGoogle Scholar
  10. 10.
    Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE (2016) Monitoring the future: national survey results on drug use 1975–2015—2015 overview: key findings on adolescent drug use. University of Michigan Institute for Social Research, Ann ArborGoogle Scholar
  11. 11.
    (2016) Cigarette smoking among US high school students at an all time low, but e-cigarette use still a concern. Centers for Disease Control and Prevention, Atlanta. http://www.cdc.gov/media/releases/2016/p0609-yrbs.html
  12. 12.
    (2014) Smoking, drinking and drug use among young people in England. Health and Social Care Information Centre, London. https://www.gov.uk/government/statistics/smoking-drinking-and-drug-use-among-young-people-in-england-2014
  13. 13.
    Biener L, Hargraves JL (2015) A longitudinal study of electronic cigarette use among a population-based sample of adult smokers: association with smoking cessation and motivation to quit. Nicotine Tob Res 17(2):127–133CrossRefPubMedGoogle Scholar
  14. 14.
    Hitchman SC, Brose LS, Brown J, Robson D, McNeill A (2015) Associations between E-cigarette Type, frequency of use, and quitting smoking: findings from a longitudinal online panel survey in Great Britain. Nicotine Tob Res 17(10):1187–1194CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Pepper JK, Ribisl KM, Emery SL, Brewer NT (2014) Reasons for starting and stopping electronic cigarette use. Int J Environ Res Public Health 11(10):10345–10361CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V (2013) Evaluating nicotine levels selection and patterns of electronic cigarette use in a group of “vapers” who had achieved complete substitution of smoking. Subst Abuse 7:139–146PubMedPubMedCentralGoogle Scholar
  17. 17.
    Farsalinos KE, Poulas K, Voudris V, Le Houezec J (2017) Prevalence and correlates of current daily use of electronic cigarettes in the European Union: analysis of the 2014 Eurobarometer survey. Intern Emerg Med. doi: 10.1007/s11739-017-1643-7 (epub ahead of print) PubMedGoogle Scholar
  18. 18.
    Caponnetto P, Saitta D, Sweanor D, Polosa R (2015) What to consider when regulating electronic cigarettes: pros, cons and unintended consequences. Int J Drug Policy. 26(6):554–559CrossRefPubMedGoogle Scholar
  19. 19.
    Polosa R, Caponnetto P, Cibella F, Le-Houezec J (2015) Quit and smoking reduction rates in vape shop consumers: a prospective 12-month survey. Int J Environ Res Public Health 12:3428–3438CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Caponnetto P, Maglia M, Polosa R, Commentary on Dawkins et al (2015) Electronic cigarettes—from smoking cessation to smoking sensation and back. Addiction 2015(110):678–679CrossRefGoogle Scholar
  21. 21.
    Adriaens K, Van Gucht D, Declerck P, Baeyens F (2014) Effectiveness of the electronic cigarette: an eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints. Int J Environ Res Public Health. 11:11220–11248CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Riccardo Polosa
    • 1
    • 2
  • Pasquale Caponnetto
    • 1
    • 2
    • 3
    Email author
  • Ray Niaura
    • 4
    • 5
  • David Abrams
    • 4
    • 5
  1. 1.Centro Prevenzione e Cura del Tabagismo, Azienda OspedalieroUniversitaria ‘‘Policlinico-V. Emanuele’’, Università di CataniaCataniaItaly
  2. 2.Dipartimento di Medicina Clinica e SperimentaleUniversità di Catania, Azienda Ospedaliero, Universitaria ‘‘Policlinico-Vittorio Emanuele’’, Università di CataniaCataniaItaly
  3. 3.Institute for Social MarketingUniversity of StirlingStirlingUK
  4. 4.The Schroeder Institute for Tobacco Research and Policy Studies at Truth InitiativeWashington, DCUSA
  5. 5.Department of HealthBehavior and SocietyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations